Last reviewed · How we verify
NCT02864602
IV Dexamethasone for Prolongation of Peripheral Nerve Block
Phase 3 trial testing IV dexamethasone in Anesthesia, Conduction in 18 participants. Completed in 20 February 2018.
20 February 2018
Quick facts
| Lead sponsor | University Health Network, Toronto |
|---|---|
| Phase | Phase 3 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | treatment |
| Enrollment | 18 |
| Start date | 12 November 2016 |
| Primary completion | 20 February 2018 |
| Estimated completion | 20 February 2018 |
| Sites | 1 location across Canada |
Drugs / interventions tested
- IV dexamethasone — full drug profile →
Conditions studied
- Anesthesia, Conduction — all drugs for Anesthesia, Conduction →
Sponsor
University Health Network, Toronto
Who can join
Adults 18 to 50, any sex, with Anesthesia, Conduction. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a volunteer study examining the effect of different doses of IV dexamethasone on prolongation of median nerve block in the forearm.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Effect of intravenous dexamethasone on the anaesthetic characteristics of peripheral nerve block: a double-blind, randomised controlled, dose-response volunteer study.
Short A, El-Boghdadly K, Clarke H, Komaba T, et al · · 2020 · cited 11× · PMID 31711605 · DOI 10.1016/j.bja.2019.08.029
Verify or expand the search:
- PubMed search for NCT02864602
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other University Health Network, Toronto trials
Trials by the same sponsor.
- NCT06831032 — Elective Adaptive Radiation With SBRT for Improved DurabilitY of Response · NA · recruiting
- NCT06634056 — Pneumonitis Prevention Protocol Using Pentoxifylline and α-tocopherol In Stage III Non-Small Cell Lung Cancer Patients U · Phase 2 · not yet recruiting
- NCT06836726 — Clinical Trial to Test Efficacy of Targeting Hypoxia Combined With ARSI After First-line ARSI Therapy for Castrate Resis · Phase 2 · not yet recruiting
- NCT07515651 — Molecular Imaging Informed Radiation Dose Escalation to Sites of Recurrent Disease and De-escalation to Uninvolved Areas · Phase 2 · not yet recruiting
- NCT07509450 — Fecal Microbiota Transplantation in Patients Undergoing Chimeric Antigen Receptor T-cell Therapy and Allogeneic Stem Cel · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02864602 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University Health Network, Toronto
- Last refreshed: 4 March 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02864602.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing